Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback